Codexis (CDXS) Projected to Post Earnings on Thursday

Codexis (NASDAQ:CDXS) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Codexis to post earnings of $0.01 per share and revenue of $35.8340 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Codexis Stock Performance

Shares of CDXS stock opened at $1.17 on Thursday. Codexis has a 52 week low of $1.12 and a 52 week high of $4.46. The firm has a 50 day moving average of $1.53 and a two-hundred day moving average of $2.08. The company has a quick ratio of 4.02, a current ratio of 4.12 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $105.67 million, a PE ratio of -1.54 and a beta of 2.46.

Wall Street Analyst Weigh In

CDXS has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Codexis in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Codexis from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of Codexis

A number of large investors have recently made changes to their positions in CDXS. Royal Bank of Canada increased its position in Codexis by 24.9% during the first quarter. Royal Bank of Canada now owns 437,126 shares of the biotechnology company’s stock worth $1,176,000 after buying an additional 87,044 shares during the period. Geode Capital Management LLC grew its position in shares of Codexis by 2.7% during the second quarter. Geode Capital Management LLC now owns 1,977,869 shares of the biotechnology company’s stock worth $4,827,000 after acquiring an additional 52,588 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Codexis by 25.9% in the 2nd quarter. Rhumbline Advisers now owns 135,556 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 27,897 shares during the period. XTX Topco Ltd purchased a new stake in Codexis in the 2nd quarter valued at $116,000. Finally, Invesco Ltd. boosted its stake in Codexis by 42.4% during the 2nd quarter. Invesco Ltd. now owns 96,078 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 28,631 shares during the period. 78.54% of the stock is owned by institutional investors and hedge funds.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.